Benitec Biopharma Inc. (BNTC) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2026, Benitec Biopharma reported revenue of $0. Net income was -$45.5M, or -$0.98 per diluted share. Operating activities generated -$16.5M of cash, leaving -$16.6M of free cash flow. At fiscal year end, Benitec Biopharma held $182.6M in total assets against $5.6M in total liabilities, including $180.0M of cash and equivalents.
Open the full interactive Benitec Biopharma financials → Quarterly statements, key ratios, valuation history and price charts.
Benitec Biopharma Key Stats
| Share Price | $8.63 |
|---|---|
| Market Cap | $401.8M |
| 52-Week Range | $8.63 – $16.52 |
| Shares Outstanding | 46.6 million (basic, 2026 Q4) |
Benitec Biopharma Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Revenue | $59,000 | $73,000 | $75,000 | $0 | $0 | $0 |
| Operating Income | -$13.6M | -$17.9M | -$19.1M | -$22.5M | -$41.8M | -$51.2M |
| Pre-Tax Income | -$13.9M | -$18.2M | -$19.6M | -$21.8M | -$37.9M | -$45.5M |
| Income Tax | — | — | — | — | — | $0 |
| Net Income | -$13.9M | -$18.2M | -$19.6M | -$21.8M | -$37.9M | -$45.5M |
| Diluted EPS | -$54.91 | -$37.91 | -$14.12 | -$5.51 | -$1.05 | -$0.98 |
Benitec Biopharma Quarterly Results
| 2026 Q1 | 2026 Q2 | 2026 Q3 | 2026 Q4 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$9.0M | -$11.8M | -$11.9M | -$12.8M |
| Diluted EPS | -$0.22 | -$0.26 | -$0.24 | -$0.28 |
Benitec Biopharma Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $19.8M | $4.1M | $2.5M | $50.9M | $97.7M | $180.0M |
| Current Assets | $20.6M | $4.8M | $3.7M | $51.7M | $98.5M | $181.7M |
| Total Assets | $21.4M | $6.0M | $4.5M | $52.2M | $99.6M | $182.6M |
| Current Liabilities | $1.4M | $2.5M | $4.0M | $4.9M | $1.8M | $5.3M |
| Total Liabilities | $1.4M | $3.1M | $4.3M | $5.0M | $2.3M | $5.6M |
| Shareholders' Equity | $20.0M | $2.9M | $202,000 | $47.2M | $97.3M | $177.0M |
Benitec Biopharma Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$12.8M | -$15.9M | -$18.0M | -$19.4M | -$23.6M | -$16.5M |
| Cash From Investing | -$221,000 | -$13,000 | -$1,000 | -$179,000 | -$18,000 | -$105,000 |
| Cash From Financing | $22.5M | — | $16.0M | $68.0M | $70.5M | $99.0M |
| Free Cash Flow | -$13.0M | -$15.9M | -$18.0M | -$19.6M | -$23.6M | -$16.6M |
Figures from Benitec Biopharma's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Benitec Biopharma financials page for every line item.
Benitec Biopharma Company Profile
| Ticker | BNTC |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Hayward, California |
| Incorporated in | Delaware |
| Fiscal Year End | June 30 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001808898 |
Frequently Asked Questions
What was Benitec Biopharma's revenue in fiscal 2026?
Benitec Biopharma (BNTC) reported revenue of $0 for fiscal 2026.
What is Benitec Biopharma's annual revenue history?
Benitec Biopharma's annual revenue by fiscal year: 2021: $59,000; 2022: $73,000; 2023: $75,000; 2024: $0; 2025: $0; 2026: $0.
What was Benitec Biopharma's net income in fiscal 2026?
Benitec Biopharma reported net income of -$45.5M for fiscal 2026.
What was Benitec Biopharma's earnings per share (EPS) in fiscal 2026?
Benitec Biopharma's diluted EPS was -$0.98 for fiscal 2026 (adjusted for any later stock splits).
How much free cash flow did Benitec Biopharma generate in fiscal 2026?
Benitec Biopharma generated -$16.6M of free cash flow in fiscal 2026.
What was Benitec Biopharma's revenue last quarter?
In its most recent reported quarter (2026 Q4), Benitec Biopharma reported revenue of $0.
How many shares of Benitec Biopharma are outstanding?
Benitec Biopharma reported a weighted average of 46.6 million basic shares outstanding in 2026 Q4.
What is Benitec Biopharma's market cap?
Based on its latest closing price, Benitec Biopharma (BNTC) has a market capitalization of about $401.8M.
When does Benitec Biopharma's fiscal year end?
Benitec Biopharma's fiscal year end, as registered with the SEC, is June 30.
Where is Benitec Biopharma headquartered?
Benitec Biopharma lists its business address in Hayward, California in its SEC filings.